# A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06605222/  
OnCo record `nct06605222` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-7787 injection in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06605222 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 201 participants planned, started 2024-10-04 and due to reach its primary completion in 2026-07-31. Interventions recorded: SHR-7787 injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06605222
- Phase: 1/2
- Setting: A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 201

## Sources

- ClinicalTrials.gov NCT06605222: https://clinicaltrials.gov/study/NCT06605222

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06605222.json